C WorldWide Group Holding A S raised its stake in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 16.0% during the second quarter, Holdings Channel reports. The firm owned 217,962 shares of the biopharmaceutical company’s stock after buying an additional 30,139 shares during the period. C WorldWide Group Holding A S’s holdings in Intra-Cellular Therapies were worth $2,707,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Norges Bank acquired a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $4,238,000. Teachers Advisors LLC raised its stake in Intra-Cellular Therapies by 0.6% in the fourth quarter. Teachers Advisors LLC now owns 70,948 shares of the biopharmaceutical company’s stock valued at $1,071,000 after buying an additional 443 shares during the period. Highbridge Capital Management LLC acquired a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $166,000. Macquarie Group Ltd. raised its stake in Intra-Cellular Therapies by 84.3% in the fourth quarter. Macquarie Group Ltd. now owns 43,500 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 19,900 shares during the period. Finally, Bank of Montreal Can raised its stake in Intra-Cellular Therapies by 699.4% in the first quarter. Bank of Montreal Can now owns 29,105 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 25,464 shares during the period. 66.60% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) opened at 11.01 on Friday. The company’s 50-day moving average is $11.97 and its 200 day moving average is $12.55. Intra-Cellular Therapies Inc. has a 52 week low of $7.85 and a 52 week high of $45.20. The stock’s market cap is $478.10 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.33. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter last year, the business earned ($0.71) EPS. The firm’s revenue was down 52.2% compared to the same quarter last year. On average, analysts expect that Intra-Cellular Therapies Inc. will post ($2.65) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/c-worldwide-group-holding-a-s-boosts-position-in-intra-cellular-therapies-inc-itci/1478007.html.

Several analysts have recently issued reports on ITCI shares. Piper Jaffray Companies lowered shares of Intra-Cellular Therapies from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $22.00 to $10.00 in a research report on Monday, May 1st. Leerink Swann lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $29.00 to $10.00 in a research report on Tuesday, May 2nd. Ladenburg Thalmann Financial Services lowered shares of Intra-Cellular Therapies from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 2nd. Cantor Fitzgerald lowered their price target on shares of Intra-Cellular Therapies from $32.00 to $29.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 2nd. Finally, Zacks Investment Research lowered shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $24.14.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.